Payment overview · 2025
General Payments
$210.46
9 reported records · 7 companies
Healthcare provider profile · identity verified
Perth Agusta Blake, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TAVARES, FL · NPI 1063505105
Verified facts
What the public records show
CMS Open Payments records show Perth Agusta Blake, M.D. received $210.46 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.03 | 20.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$36.42 | 17.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.71 | 16.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.10 | 15.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.84 | 11.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.27 | 9.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.09 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $210.46 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $44.03 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $44.03 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.03 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $36.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.71 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 393 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 62 |
| Lorazepam | Lorazepam | 174 | 33 |
| Tramadol Hcl | Tramadol Hcl | 166 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 49 |
| Lisinopril | Lisinopril | 158 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 45 |
| Metformin Hcl | Metformin Hcl | 157 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 46 |
| Famotidine | Famotidine | 123 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 32 |
| Gabapentin | Gabapentin | 106 | 32 |
| Losartan Potassium | Losartan Potassium | 100 | 39 |
| Alprazolam | Alprazolam | 99 | 18 |
| Glipizide | Glipizide | 96 | 28 |
| Potassium Chloride | Potassium Chloride | 96 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 31 |
| Eliquis | Apixaban | 95 | 26 |
| Pregabalin | Pregabalin | 94 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 33 |
| Furosemide | Furosemide | 87 | 33 |
| Carvedilol | Carvedilol | 85 | 25 |
| Omeprazole | Omeprazole | 84 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 27 |
| Meloxicam | Meloxicam | 77 | 35 |
| Metformin Hcl Er | Metformin Hcl | 73 | 21 |
| Mirtazapine | Mirtazapine | 73 | 23 |
| Montelukast Sodium | Montelukast Sodium | 69 | 24 |
| Methylprednisolone | Methylprednisolone | 62 | 50 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 19 |
| Sertraline Hcl | Sertraline Hcl | 62 | 19 |
| Trazodone Hcl | Trazodone Hcl | 62 | 18 |
| Simvastatin | Simvastatin | 61 | 22 |
| Clonazepam | Clonazepam | 58 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Fenofibrate | Fenofibrate | 57 | 13 |
| Glipizide Er | Glipizide | 56 | 18 |
| Jardiance | Empagliflozin | 54 | 15 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 50 | 14 |
| Nifedipine Er | Nifedipine | 48 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | 14 |
| Baclofen | Baclofen | 47 | 14 |
| Benazepril Hcl | Benazepril Hcl | 46 | 14 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 22 |
| Methocarbamol | Methocarbamol | 43 | 17 |
| Ezetimibe | Ezetimibe | 42 | 14 |
| Alendronate Sodium | Alendronate Sodium | 41 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 18 |
| Lovastatin | Lovastatin | 36 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 13 |
| Celecoxib | Celecoxib | 34 | 17 |
| Diazepam | Diazepam | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 27 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 33 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 32 | suppressed |
| Naproxen | Naproxen | 32 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 29 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 11 |
| Meclizine Hcl | Meclizine Hcl | 26 | 15 |
| Ozempic | Semaglutide | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 18 |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Estradiol | Estradiol | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $210.46 · 9 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, CAPVAXIVE, COMIRNATY, GARDASIL 9, MINIMED 780G, Ozempic, PREVNAR 20, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error